anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Children with extreme short stature and their families frequently experience significant psychological stress related to concerns about adult height. Additionally, extreme short stature often presents life-long emotional, social, and physical obstacles to the affected individual. The onset of puberty in such patients presents a critical management problem because puberty initiates the process of epiphyseal closure that terminates linear growth. Until recently, there was no way to delay the onset of puberty in such patients. The development of synthetic LHRH analogs, however, has provided such a method. Administration of such analogs to children with precocious puberty caused a regression of their clinical signs of puberty, a decrease in their gonadotropins and sex steroids, and a slowing of the rate of bone age advancement.

We propose to treat pubertal children with extreme short stature with a long-acting analog of luteinizing hormone-releasing hormone (D-Trp6-Pro9-NEt-LHRHa). The goal of LHRHa treatment in these children is to halt the normal progression into puberty and thereby delay epiphyseal fusion. We postulate that delay of puberty will prolong pre-pubertal growth prior to the pubertal spurt and subsequent epiphyseal fusion, and thus will enhance ultimate height. This study will test this hypothesis through a double-blind, randomized comparison of the effect of LHRHa and placebo on final adult height. Patients will be treated with LHRHa or placebo for 4 years, and will then be followed until they have completed puberty and have stopped growing.
A novel means of immunological therapy for cancer. More particularly speaking, remedies for cancer or health-promoting food preparations each containing a substance capable of activating NKT cells which are remedies for cancer to be administered with the use of the abilities to induce IL-12 production and to activate NKT cells as a guidance or health-promoting foods to be orally taken with the expectation of achieving an anticancer effect. Compositions having at least an ability to induce the IL-12 production and another ability to activate NKT cells which contain processed Schizophyllum commune Fr. mycelia or a mixture of at least two members selected from among polysaccharides originating in culture filtrate of Schizophyllum commune Fr. mycelia, processed Lentinus edodes mycelia and processed Ganoderma lucidum (Fr.) Karst mycelia. Novel IL-12 production inducers and novel NKT cell activators.
BACKGROUND: In hepatocellular carcinoma (HCC) treatment, first-line targeted therapy in combination with immune checkpoint inhibitors (ICIs) has improved patient prognosis, but the 5-year survival rate is far from satisfactory. Studies have shown that the extracellular matrix (ECM) is an essential part of the tumour microenvironment (TME) and participates in the progression of malignant tumours. ECM remodelling can enhance matrix stiffness in cirrhosis patients, induce an immunosuppressive microenvironment network, and affect the efficacy of targeted therapies and ICIs for treating HCC. However, the exact mechanism is still unclear.
METHODS: We downloaded data from public databases, selected differentially expressed ECM proteins associated with matrix stiffness, constructed and validated a prognostic model of HCC using Lasso Cox regression, and investigated the roles and mechanism of one of the ECM proteins, dynein light chain LC8-type 1 (DYNLL1), in HCC proliferation, migration, and apoptosis via in vitro experiments.
RESULTS: In this study, the risk score of the matrix stiffness-related ECM protein model effectively predicted the prognosis of HCC patients. The high- and low-risk subgroups of the model also showed differences in immune cells, immune functions, and drug sensitivity. DYNLL1 promoted HCC cell progression and migration and inhibited HCC cell apoptosis through the Wnt/β-catenin pathway in vitro.
CONCLUSION: The expression of matrix stiffness-related ECM proteins could be an independent predictor of HCC prognosis. DYNLL1, an oncogenic gene in HCC, has the potential to be a new target for HCC treatment.
PROBLEM TO BE SOLVED: To obtain the subject treating medicine fee from fear of adverse effects, prolongation of treating period, relapse, etc., after treatment and capable of commonly applying to various kinds of poisonous sources by compounding a trace amount of nontoxic aconite tuber with mica, crystalline sulfur and burnt alum. SOLUTION: This treating medicine comprises (A) 75-80 pts.wt. crystalline sulfur (e.g. sulfur obtained by heating and melting crude crystal sulfur at 120 deg.C, removing floating impurities, solidifying the melted sulfur with cooling water, then drying the solidified sulfur and dissolving the dried sulfur in carbon disulfide, filtering the solution and recovering from the filtrate, (B) a nontoxic aconite tuber (e.g. aconite tuber obtained by pouring 60% ethanol aqueous solution into aconite tuber, heat-treating the aconite tuber at 110-120 deg.C, removing an aconite-based alkaloid by extraction and drying and powdering the residual part, (C) 5-7 pts.wt. mica and (D) 0.8-0.9 pt.wt. burnt alum. The treating medicine is prepared in a dosage form of pill, capsule, etc., and the components A, B, C and D are preferably each included in amounts of 400mg, 4mg, 20mg and 5mg.
Placement of a delayed intermediate abutment (in the second implant surgery). This abutment has a height of 3 mm.
PROBLEM TO BE SOLVED: To provide application of Chinese herbal medicine composition in preparation of health food or medicament for alleviation of physical fatigue and prevention therapy.SOLUTION: Chinese herbal medicine composition consisting of 5 to 90 pts.wt. of American Ginseng, 5 to 160 pts.wt. of Ganoderma lucidum, 1 to 90 pts.wt. of bacterial powder of fermented Ophiocordyceps sinensis, and/or 1 to 120 pts.wt. of Ophiocordyceps sinensis derived from Chinese medicinal herb or Chinese herbal medicine extract corresponding to herbal medicine dose may be supplied with additional 5 to 90 pts.wt. Rosa rugosa Thunb. The present invention further relates to application of the composition in preparation of health food or medicament for reducing blood lipid and prevention therapy, relates to application in preparation of health food or medicament for prevention and prevention therapy of oxidation, and relates to application in preparation of health food or medicament for improvement and prevention therapy in low oxygen resistance. The present invention may be prepared in any agent form containing pharmaceutically acceptable sub ingredient.SELECTED DRAWING: None
A research participant was monitored over nearly two decades at Mayo Clinic, undergoing annual neurologic assessments, neuropsychological tests, and multimodal imaging. Initially, he was cognitively normal but developed symptoms consistent with Posterior Cortical Atrophy (PCA) during the study. Early tests indicated mild, yet normal-range declines in language and visuospatial skills. FDG-PET scans revealed increased metabolism in posterior brain regions long before symptoms appeared. Advanced analysis using a novel in-house machine-learning tool predicted concurrent Alzheimer's disease and dementia with Lewy bodies. Autopsy confirmed a mixed neurodegenerative condition with significant Alzheimer's pathology and dense neocortical Lewy bodies. This case underscores the value of longitudinal imaging in predicting complex neurodegenerative diseases, offering vital insights into the early neurocognitive changes associated with PCA and dementia with Lewy bodies.
A method is provided for performing exercise therapy and rehabilitation. A first therapy module can be performed. The first therapy module comprises at least one first physical metric for rotating, by a resistance device, at least one joint of a limb of a user. At least one psychophysical metric and at least one physical metric of the user can be monitored while performing the first therapy module. Psychophysical metric data for the at least one psychophysical metric and physical metric data for the at least one physical metric can be received. Based on at least one of the psychophysical metric data and the physical metric data, the at least one first physical metric for rotating the at least one joint of the limb by the resistance device while performing the first therapy module can be modified.
PROBLEM TO BE SOLVED: To obtain a liquid agent for internal use, compounded with a sugar alcohol and having improved taste and flavor by including a mixed fruit-type flavor. SOLUTION: This agent is produced by compounding a liquid agent containing a sugar alcohol with a mixed fruit-type flavor selected from peach-note, grape- note, lychee-note, apricot-note and strawberry-note flavor. It is further compounded with an acid such as malic acid and citric acid, a sweetener such as trehalose, palatinose and stevia, etc. The sugar alcohol is e.g. erythritol, maltitol, sorbitol, xylitol, etc., and the amount of the mixed fruit-type flavor is 0.0045-0.045 pt.wt. based on 1 pt.wt. of the sugar alcohol. The taste of the agent is not deteriorated even by compounding an active component such as biotin having a stability problem in the presence of a reducing sugar.
Clinical studies of dronabinol capsules in AIDS and cancer patients did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

Elderly patients may be more sensitive to the neuropsychiatric and postural hypotensive effects of SYNDROS [see Warnings and Precautions (5.1, 5.2)].

Elderly patients with dementia are at increased risk for falls as a result of their underlying disease state, which may be exacerbated by the CNS effects of somnolence and dizziness associated with SYNDROS [see Warnings and Precautions (5.1)]. These patients should be monitored closely and placed on fall precautions prior to initiating SYNDROS therapy. In antiemetic studies, no difference in efficacy was apparent in patients greater than 55 years of age compared to younger patients.

In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of falls, decreased hepatic, renal, or cardiac function, increased sensitivity to psychoactive effects, and of concomitant disease or other drug therapy [see Dosage and Administration (2.2, 2.3)].
The removable Vacuum-formed retainers were made of acetate 1mm thickness. They were made at the same appointment of debonding using plaster models. The patients were instructed to use the retainers only during nights.
INTRODUCTION: There is a lack of reliable predictors of disease behavior progression in patients with Crohn's disease (CD). Real-time shear-wave elastography (SWE) is a novel method for evaluating tissue stiffness. However, its value for assessing CD has not yet been investigated. We aimed to explore the value of SWE and other ultrasound parameters at diagnosis in predicting CD behavior progression.
METHODS: We retrospectively collected data from patients with CD with the nonstenotic nonpenetrating disease (B1 phenotype based on the Montreal classification). All patients underwent intestinal ultrasound at baseline and were followed up. The end point was defined as disease behavior progression to stricturing (B2) or penetrating (B3) disease. Cox regression analysis was performed for the association between baseline characteristics and subsequent end points. In addition, a multivariate nomogram was established to predict the risk of disease behavior progression quantitatively.
RESULTS: A total of 130 patients with CD with B1 phenotype were enrolled. Twenty-seven patients (20.8%) developed B2 or B3 disease, with a median follow-up of 33 months. Multivariate analysis identified that SWE was the only independent predictor of disease behavior progression (hazard ratio 1.08, 95% confidence interval 1.03-1.12, P = 0.001). A reverse of the HR appeared at the cutoff 12.75 kPa. The nomogram incorporating SWE and other clinical characteristics showed a good prediction performance (area under the curve = 0.792).
DISCUSSION: Intestinal stiffness assessed using SWE is an independent predictor of disease behavior progression in patients with CD. Patients with CD with SWE >12.75 kPa at diagnosis are prone to progress toward stricturing or penetrating diseases.
Perfluoroundecanoic acid (PFDA) is extensively utilized in the textile and food processing industries and may have a tumor-promoting effect by modulating the tumor microenvironment. Macrophages play crucial roles in tumor microenvironment as key regulators of tumor immunity. However, further investigation is needed to elucidate how PFDA interacts with macrophages and contributes to tumor progression. In this study, we treated the macrophage cell line RAW264.7 with various concentrations of PFDA and found that RAW264.7 transitioned into an M2 tumor-promoting phenotype. Through bioinformatic analysis and subsequent verification of molecular assays, we uncovered that PFDA could activate β-catenin and enhance its nuclear translocation. Additionally, it was also observed that inhibiting β-catenin nuclear translocation partly attenuated RAW264.7 M2 polarization induced by PFDA. The conditioned medium derived from PFDA-pretreated RAW264.7 cells significantly promoted the migration and invasion abilities of human ovarian cancer cells. Furthermore, in vivo studies corroborated that PFDA-pretreated RAW264.7 could promote tumor metastasis, which could be mitigated by pretreatment with the β-catenin inhibitor ICG001. In conclusion, our study demonstrated that PFDA could promote cancer metastasis through regulating macrophage M2 polarization in a Wnt/β-catenin-dependent manner.
A substantially pure protein, Gab1, that binds to Grb2 is disclosed. Isolated nucleic acid molecules that encode Gab1 is disclosed. Pharmaceutical compositions comprising a pharmaceutically acceptable carrier in combination with nucleic acid molecules are disclosed. Fragments of nucleic acid molecules that encode Gab1 having at least 10 nucleotides and oligonucleotide molecule comprising a nucleotide sequence complimentary to a nucleotide sequence of at least 10 nucleotides are disclosed. Recombinant expression vectors that comprise the nucleic acid molecule that encode Gab1, and host cells that comprise such recombinant vectors are disclosed. Antibodies that bind to an epitope on Gab1 are disclosed. Methods of identifying inhibitors, activators and substrates of Gab1 are disclosed. Antisense compounds and methods of using the same are disclosed.
Wheat germ energy balls containing 30 g of wheat germ, peanut butter, and honey to form 2 energy balls that is approximately 200 kcal. Two energy balls will be consumed daily for 30 days.
Metastatic patients with grade 1 anemia and on treatment with anti-CDK 4/6 or PARP Inhibitors (10 patients) or on adjuvant therapy with hormonal therapy (10 patients) will be enrolled. The control of the event will be evaluated during treatment with 40 drops TID of Stinging Nettle Fluid Extract; hemoglobin levels will be assessed every 4 weeks for a maximum period of 6 months.
Understanding the interactions between genetic risk and lifestyles on different types and age onsets of cardiovascular disease (CVD) risk can help identify individuals for whom lifestyle changes would be beneficial. Here we developed three polygenic risk scores, called MetaPRSs, for coronary artery disease, ischaemic stroke and intracerebral haemorrhage by combining PRSs for CVD and CVD-related risk factors in 96,400 participants from the prospective China Kadoorie Biobank. Genetic and lifestyle risks were categorized by the disease-specific MetaPRSs and the number of unfavourable lifestyles. High genetic risk and unfavourable lifestyles were found to be more strongly associated with early than late onset of CVD outcomes in men and women. Change from unfavourable to favourable lifestyles resulted in 14.7-, 2.5- and 2.6-fold greater reductions in incidence rates of early-onset coronary artery disease and ischaemic stroke and late-onset coronary artery disease in high than low genetic risk group. Young adults at high genetic risk may have larger benefits in preventing CVD from lifestyle improvements.
The invention relates to an application of D-seromycin in preparing medicine for treating Morphine psychological dependence behavior caused by stress, which belongs to the medicine technical field. A glutamic acid system in brain plays an important role in drug addiction process, and N-methyl-D-aspartic acid (NMDA) receptor which can be combined with glutamic acid to play a physiological effect exists in central nervous system. The NMDA receptor can be functionally inhibited by acting on different recognition sites. At present more side effects are brought by completely inhibiting the NMDA receptor, so antagonist which not only can block the pathological activation of the NMDA receptor but also is free from influencing the physiological activity of the NMDA receptor is important to discover. DCS is a serine natural derivative and is combined with a glycine site in NMDA receptor NR1 subunit to play an effect of excitant, so that internal flow of calcium ions in cells can be increased, but no neurotoxicity is produced. Since the prepared medicine not only can partially excite the NMDA receptor, but also is free from influencing the physiological activity, the medicine has small side effect on the human body.
Subjects undergoing abdominal hysterectomy often experience moderate to severe acute pain post-surgery. Normally such pain is controlled when subjects receive repeated doses of opioid analgesics. However, opioid therapy is commonly associated with side effects such as nausea, vomiting, sedation, constipation, addiction, tolerance, and respiratory depression. Tapentadol (CG5503), a newly synthesized drug with an immediate release (IR) formulation, also acts as a centrally acting pain reliever but has a dual mode of action. The aim of this study is to investigate the effectiveness (level of pain control) and safety (side effects) of 3 dose levels of CG5503 IR compared with no drug (placebo) or one dose level of morphine (an opioid commonly used to treat post-surgical pain). This study is a randomized, double-blind (neither investigator nor patient will know which treatment was received), active- and placebo-controlled, parallel-group, multicenter study to evaluate the treatment of acute pain after abdominal hysterectomy. The study will include a blinded 72 hour in-patient phase immediately following hysterectomy, during which subjects will be treated with either 50-, 75-, or 100-mg CG5503 IR, a matched placebo, or 20-mg morphine, and pain relief will be periodically assessed. Assessments of pain relief include the pain intensity numeric rating scale (PI), pain relief numeric rating scale (PAR), and patient global impression of change scale (PGIC). Safety evaluations include monitoring of adverse events, physical examinations, and clinical laboratory tests. Venous blood samples will be collected for the determination of serum concentrations of CG5503 and morphine. The alternative study hypothesis is that at least 1 dose strength of CG5503 will be different from placebo in controlling pain at 24 hours (using the mean SPID at 24 hours).
PURPOSE: To describe and evaluate a novel method to determine the validity of measurements made using cycle-by-cycle (CxC) recording techniques in patients with advanced retinal degenerations (RD) having low-amplitude flicker electroretinogram (ERG) responses.
METHODS: The method extends the original CxC recording algorithm introduced by Sieving et al., retaining the original recording setup and the preliminary analysis of raw data. Novel features include extended use of spectrum analysis, reduction of errors due to known sources, and a comprehensive statistical assessment using three different tests. The method was applied to ERG recordings from seven patients with RD and two patients with CNGB3 achromatopsia.
RESULTS: The method was implemented as a Windows application to processes raw data obtained from a commercial ERG system, and it features a computational toolkit for statistical assessment of ERG recordings with amplitudes as low as 1 µV, commonly found in advanced RD patients. When recorded using conditions specific for eliciting cone responses, none of the CNGB3 patients had a CxC validated response, indicating that no signal artifacts were present with our recording conditions. A comparison of the presented method with conventional 30 Hz ERG was performed. Bland-Altman plots indicated good agreement (mean difference, -0.045 µV; limits of agreement, 0.193 to -0.282 µV) between the resulting amplitudes. Within-session test-retest variability was 15%, comparing favorably to the variability of standard ERG amplitudes.
CONCLUSIONS: This novel method extracts highly reliable clinical recordings of low-amplitude flicker ERGs and effectively detects artifactual responses. It has potential value both as a cone outcome variable and planning tool in clinical trials on natural history and treatment of advanced RDs.
ETHNOPHARMACOLOGICAL RELEVANCE: Mandevilla velutina (Mart. Ex Stadelm.) Woodson, known in Brazil as "infalível" and "jalapa", is a medicinal plant native from the Cerrado region (Brazilian Savannah). The underground organ (xylopodium) of this species is prepared as ethanolic extract or infusion and it is commonly used in traditional medicine to treat snake venom. Although, locals and indigenous populations from Cerrado have used M. velutina for the treatment of infection by Trypanosoma cruzi (Chagas' disease).
AIM OF THE STUDY: This study aimed to evaluate the in vitro antioxidant and anti-glycation activities of the crude hydroethanolic extract of M. velutina xylopodium. Besides, it aimed to evaluate its effect on parasitemia levels in vivo T. cruzi experimental infection. In addition, this study aimed to determine possible interactions between the main compound of the extract and molecular targets associated with survival and virulence of T. cruzi in silico approaches.
MATERIALS AND METHODS: Determination of total polyphenols, flavonoids and steroidal aglycones content were performed. In addition, high performance liquid chromatography (HPLC) was carried out to identify main compounds of the extract. Antioxidant activity was determined by DPPH radical scavenging, ferric ion reducing power (FRAP), Thiobarbituric acid reactive species (TBARS) and Oxygen Radical Absorbance Capacity (ORAC) methods. Anti-glycation activity was demonstrated through relative mobility in electrophoresis (RME), determination of free amino groups and inhibition of AGEs formation. Determination of the action of extract in parasitemia levels was performed by T. cruzi experimental infection of mice and nitrite levels were measured in the serum of animals evaluated in this study. Molecular docking analyses of the main compound (Velutinol A) with DNA and molecular targets associated with survival and virulence of T. cruzi.
RESULTS: Phytoconstituents evaluation exhibited the presence polyphenols, flavonoids and steroidal aglycone, and HPLC identified the major presence of Velutinol A. Antioxidant and anti-glycation evaluations showed that the extract present significant activity in all methods evaluated. In addition, extract reduced the number of trypomastigotes and increased the survival of treated animals. The treatment using extract showed an interference in the synthesis of physiological nitric oxide as an immune response to infection. In silico assays demonstrated interaction between Velutinol A and DNA and molecular targets of T. cruzi.
CONCLUSIONS: The results showed that the hydroethanolic extract of M. velutina xylopodium contains bioactive compounds including polyphenols, flavonoids and steroidal aglycones (mainly Velutinol A) of which may be responsible for the antioxidant, anti-glycation and anti-parasitic activity against T. cruzi. Trypanocidal activity of M. velutina compounds may be linked to their influence on NO synthesis during infection and/or their capacity to bind and inhibit molecules associated to virulence and survival of T. cruzi.